Osteoporosis: how should it be treated? - Wikidata - awgldk - TriplyDB

Osteoporosis: how should it be treated?

Osteoporosis: how should it be treated?

http://www.wikidata.org/entity/Q36583646

about

Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone Local application of an ibandronate/collagen sponge improves femoral fracture healing in ovariectomized rats.

P2860

Q35085185-B474E698-6EDF-43C9-97DF-00251B904B32 Q43419291-B209FC01-1A3A-4DE5-AFCA-95635A6D925C

P2860

Osteoporosis: how should it be treated?

http://www.wikidata.org/entity/Q36583646

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Osteoporosis: how should it be treated?

@ast

Osteoporosis: how should it be treated?

@en

type

label

Osteoporosis: how should it be treated?

@ast

Osteoporosis: how should it be treated?

@en

prefLabel

Osteoporosis: how should it be treated?

@ast

Osteoporosis: how should it be treated?

@en

P1433

Q36583646-97A18DB8-27D6-4E19-9292-88F03DDE4375

P1476

Q36583646-F0AA94F1-EE03-41D0-B8B4-A70597D80938

P2093

Q36583646-45093C8B-5058-4A9F-92A4-D8558B54A49B

P2860

Q36583646-06476D1E-E9FC-4FD6-B177-D6656D98B76A

Q36583646-084C6E37-9BD8-40F7-BDB2-EB0C77DF2390

Q36583646-0C115F58-77B1-4039-A161-271F4E3ED5BF

Q36583646-0EB6000C-9CFA-4882-A627-8DA6DB7AE28F

Q36583646-1227FB99-86A9-4D73-BF56-457BD26F9571

Q36583646-157AD829-B70B-4B64-BD98-7EE0873E1279

Q36583646-1BB36D89-59F2-4999-B80A-1430BFA0945C

Q36583646-1F571AE3-B67B-4327-B0C7-DB0DE274E7FD

Q36583646-248926A0-8B5D-4429-8E08-20FC0AC1996B

Q36583646-2CF9F5E0-1B34-4E68-B93B-852C162A285A

P304

Q36583646-B8B2B989-203D-4166-9E39-F31BFE3601E4

P31

Q36583646-76B01C92-22C0-471D-8343-4FD5F2208D67

P356

Q36583646-A5FD8504-69FC-4814-9802-C52E2FC69B2F

P433

Q36583646-E25CC084-6B7D-4961-9841-6D834C74628D

P478

Q36583646-CC07F680-609E-4B1D-B6C4-15A2F5BA7068

P577

Q36583646-F989152D-5F1F-418C-88ED-F75AD654D7B7

P698

Q36583646-30F46CDA-7174-4FD9-B536-AE453A4B234D

P921

Q36583646-B6DDF6C6-A814-4459-A4A5-6A0B38A6DD4C

P356

6650.2006.05037

P1433

Journal of Investigative Medicine

P1476

Osteoporosis: how should it be treated?

@en

P2093

Clarita V Odvina

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites

Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids.

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients.

The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime.

P304

114-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2310/6650.2006.05037

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P577

2006-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16948394

http://www.w3.org/2001/XMLSchema#string

P921